company background image

Xenetic Biosciences NasdaqCM:XBIO Stock Report

Last Price


Market Cap







25 Sep, 2022


Company Financials +
XBIO fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health6/6

XBIO Stock Overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.

Xenetic Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xenetic Biosciences
Historical stock prices
Current Share PriceUS$0.59
52 Week HighUS$2.37
52 Week LowUS$0.45
1 Month Change-23.86%
3 Month Change-18.86%
1 Year Change-73.59%
3 Year Change-53.84%
5 Year Change-97.58%
Change since IPO-99.98%

Recent News & Updates

Aug 12

Xenetic Biosciences reports Q2 results

Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss of $2.7M The Company ended the quarter with approximately $14.9 million of cash. Shares +7.9% PM.

Aug 02

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Biopharmaceutical firm Xenetic Biosciences (NASDAQ:XBIO) and VolitionRx (NYSE:VNRX), a developer of blood tests, have signed a research and development agreement for certain targeted cell therapies to treat cancer, the companies said on Tuesday. Xenetic (XBIO) stock had lost 5.4% to $0.87 in premarket trading, while shares of VolitionRx (VNRX) had gained 6.5% to $2.13. VNRX separately announced another R&D collaboration agreement with Salarius Pharmaceuticals (SLRX). XBIO and VNRX will develop neutrophil extracellular traps (NETs) which are net-like structures composed of DNA complexes and proteins. They are involved in cancer progression and metastatic dissemination. The R&D collaboration will evaluate the potential combination of VNRX's Nu.Q NETs Test and XBIO's CAR-T platform to develop cell therapies for the potential treatment of cancer. VolitionRx (VNRX) will fund the research program and the two parties will share proceeds from any products licensed or commercialized under the collaboration.

Jul 07

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences (NASDAQ:XBIO) said it engaged Catalent (NYSE:CTLT) to manufacture the company's recombinant protein Human DNase 1 for use in a cancer study. Catalent Pharma Solutions will carry out the cGMP manufacturing of DNase to help Xenetic advance to a phase 1 study, according to a July 7 press release. "We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin to support the advancement of Xenetic's DNase clinical development program and accelerating their path to first-in-human studies," said Vikalp Mohan, global vice president, head of Drug Substance at Catalent Biologics Xenetic said its interventional DNase based cancer platform is aimed at improving outcomes of existing treatments, including immunotherapies.

Shareholder Returns

XBIOUS BiotechsUS Market

Return vs Industry: XBIO underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: XBIO underperformed the US Market which returned -23% over the past year.

Price Volatility

Is XBIO's price volatile compared to industry and market?
XBIO volatility
XBIO Average Weekly Movement10.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: XBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: XBIO's weekly volatility (10%) has been stable over the past year.

About the Company

n/a4Jeff Eisenberg

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Xenetic Biosciences Fundamentals Summary

How do Xenetic Biosciences's earnings and revenue compare to its market cap?
XBIO fundamental statistics
Market CapUS$8.39m
Earnings (TTM)-US$7.46m
Revenue (TTM)US$1.49m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XBIO income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$1.49m
Other ExpensesUS$8.95m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.52
Gross Margin100.00%
Net Profit Margin-501.38%
Debt/Equity Ratio0%

How did XBIO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is XBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XBIO?

Other financial metrics that can be useful for relative valuation.

XBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does XBIO's PS Ratio compare to its peers?

XBIO PS Ratio vs Peers
The above table shows the PS ratio for XBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average17.5x
LOGC LogicBio Therapeutics
BIOC Biocept
SBFM Sunshine Biopharma
STAB Statera Biopharma
XBIO Xenetic Biosciences

Price-To-Sales vs Peers: XBIO is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (17.5x).

Price to Earnings Ratio vs Industry

How does XBIO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: XBIO is good value based on its Price-To-Sales Ratio (5.6x) compared to the US Biotechs industry average (12.5x)

Price to Sales Ratio vs Fair Ratio

What is XBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.6x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: XBIO is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Share Price vs Fair Value

What is the Fair Price of XBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XBIO's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Xenetic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XBIO's revenue (10.3% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: XBIO's revenue (10.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XBIO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Xenetic Biosciences performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: XBIO is currently unprofitable.

Growing Profit Margin: XBIO is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: XBIO is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

Accelerating Growth: Unable to compare XBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: XBIO has a negative Return on Equity (-49.1%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Xenetic Biosciences's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: XBIO's short term assets ($15.4M) exceed its short term liabilities ($1.3M).

Long Term Liabilities: XBIO has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: XBIO is debt free.

Reducing Debt: XBIO had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XBIO has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 1.1% each year.

Discover healthy companies


What is Xenetic Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate XBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBIO's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XBIO has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Jeff Eisenberg (56 yo)





Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...

CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD750.23K) is about average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: XBIO's management team is seasoned and experienced (5.4 years average tenure).

Board Members

Experienced Board: XBIO's board of directors are considered experienced (3.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of XBIO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders186,7811.3%
Public Companies447,1223.1%
General Public12,647,85188.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.5%.

Top Shareholders

Top 17 shareholders own 11.66% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
The Vanguard Group, Inc.
616,467$361.4k0%no data
Public Joint-Stock Company "Pharmsynthez"
447,122$262.1k0%no data
Alexey Vinogradov
186,781$109.5k0%no data
Renaissance Technologies LLC
151,058$88.6k-21.08%no data
Geode Capital Management, LLC
92,601$54.3k1.82%no data
Susquehanna International Group, LLP, Asset Management Arm
37,517$22.0k0%no data
State Street Global Advisors, Inc.
34,668$20.3k0%no data
Royal Bank of Canada Trust Company (Bahamas) Limited, Asset Management Arm
26,991$15.8k0%no data
Steward Partners Investment Advisory, Llc
19,000$11.1k0%no data
Northern Trust Global Investments
17,760$10.4k0%no data
Tower Research Capital LLC
14,379$8.4k697.5%no data
Morgan Stanley, Investment Banking and Brokerage Investments
12,654$7.4k-0.09%no data
Great Valley Advisor Group, Inc.
10,600$6.2k0%no data
UBS Asset Management
919$538.80%no data
Crewe Advisors Llc
115$67.40%no data
Wells Fargo & Company, Private Banking and Investment Banking Arm
88$51.615.79%no data
Strategic Advisers LLC
25$14.70%no data

Company Information

Xenetic Biosciences, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Xenetic Biosciences, Inc.
  • Ticker: XBIO
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$8.393m
  • Shares outstanding: 14.32m
  • Website:

Number of Employees


  • Xenetic Biosciences, Inc.
  • 40 Speen Street
  • Suite 102
  • Framingham
  • Massachusetts
  • 1701
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2014
3XBDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.